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Background: The present study was designed to evaluate the relationship between high-sensitivity C-reactive
protein (hs-CRP) and arterial stiffness according to sex in patients with arterial hypertension.
Methods: A case-series study was carried out in 258 hypertensive patients without antecedents of cardiovascular
disease or diabetes mellitus. Nephelometry was used to determine hs-CRP. Office or clinical and home blood
pressures were measured with a validated OMRON model M10 sphygmomanometer. Ambulatory blood pressure
monitoring was performed with the SpaceLabs 90207 system. Pulse wave velocity (PWV) and central and peripheral
augmentation index (AIx) were measured with the SphygmoCor system, and a Sonosite Micromax ultrasound unit
was used for automatic measurements of carotid intima-media thickness (IMT). Ambulatory arterial stiffness index
and home arterial stiffness index were calculated as “1-slope” from the within-person regression analysis of
diastolic-on-systolic ambulatory blood pressure.
Results: Central and peripheral AIx were greater in women than in men: 35.31 ± 9.95 vs 26.59 ± 11.45 and
102.06 ± 20.47 vs 85.97 ± 19.13, respectively. IMT was greater in men (0.73 ± 0.13 vs 0.69 ± 0.10). hs-CRP was positively
correlated to IMT (r = 0.261), maximum (r = 0.290) and to peripheral AIx (r = 0.166) in men, and to PWV in both men
(r = 0.280) and women (r = 0.250). In women, hs-CRP was negatively correlated to central AIx (r =−0.222). For each
unit increase in hs-CRP, carotid IMT would increase 0.05 mm in men, and PWV would increase 0.07 m/sec in men
and 0.08 m/sec in women, while central AIx would decrease 2.5 units in women. In the multiple linear regression
analysis, hs-CRP explained 10.2% and 6.7% of PWV variability in women and men, respectively, 8.4% of carotid IMT
variability in men, and 4.9% of central AIx variability in women.
Conclusions: After adjusting for age, other cardiovascular risk factors and the use of antihypertensive and
lipid-lowering drugs, hs-CRP was seen to be positively correlated to carotid IMT in men, and negatively correlated
to central AIx in women. The association of hs-CRP to arterial stiffness parameters differs between men and women.
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The association of high-sensitivity CRP (hs-CRP) to car-
diovascular morbidity-mortality has not been sufficiently
clarified. Some studies have identified hs-CRP as an in-
dependent predictor of cardiovascular events, hyperten-
sion and diabetes [1-3]. It offers prognostic information
additional to that of the classical factors used to estimate
cardiovascular risk, and reclassifies a substantial propor-
tion of “intermediate risk” individuals as presenting high
risk [3,4]. Kaptoge et al. [5], in a metaanalysis of 160,309
patients without antecedents of cardiovascular disease,
concluded that hs-CRP concentration shows a continu-
ous association to the risk of coronary disease, cerebral
thrombosis and cardiovascular mortality. Nevertheless,
this association is conditioned by the conventional
cardiovascular risk factors. However, its role in the
pathogenesis of arteriosclerosis has not been demon-
strated [1,6-8].
The studies that analyze the relationship between
hs-CRP and arterial stiffness, as well as behavior accord-
ing to sex, are inconclusive [9-11]. A prospective study
in males subjected to 20 years of follow-up has con-
cluded that pulse wave velocity (PWV) is related to cu-
mulative exposure to hs-CRP, while the augmentation
index (AIx) is more related to the values present at the
time of analysis [12]. Regarding the relationship between
hs-CRP and intima-media thickness (IMT), a number of
studies have reported a positive correlation, particularly
in hypertensive elderly individuals [8,13], while another
study has only found an association in women [14]. The
association of the different arterial stiffness measures to
hs-CRP and its behavior according to sex in hypertensive
individuals have not been studied to date. The present
study was designed to evaluate the relationship between
hs-CRP and arterial stiffness as evaluated by carotid
IMT, PWV, central and peripheral AIx, ambulatory ar-
terial stiffness index (AASI) and home arterial stiffness
index (HASI) according to sex in patients with primary
arterial hypertension.
Methods
Study design and population
A cross-sectional study was carried out in a primary care
setting. We consecutively included all hypertensive sub-
jects visiting primary care clinics between January 2008
and January 2011, and referred to the research unit for
the assessment of cardiovascular risk. Hypertension was
diagnosed when the mean of three recordings in the
clinic under basal conditions and separated in time
revealed systolic blood pressure (SBP) ≥140 and/or dia-
stolic blood pressure (DBP) ≥ 90 mmHg. On each visit at
least two recordings were made, spaced more than one
minute apart. The included 258 hypertensive patients
were aged 30–80 years without history of cardiovasculardisease (ischemic heart disease or stroke) or diabetes
mellitus. Sample size calculation indicated that the 258
patients included in the study were sufficient to detect a
minimum correlation coefficient between hs-CRP and
arterial stiffness parameters of 0.20 in a two-sided test,
with a significance level of 0.05 and a power of 0.90. The
study was approved by an independent ethics committee
of Salamanca University Hospital (Spain), and all partici-
pants gave written informed consent according to the gen-
eral recommendations of the Declaration of Helsinki [15].Measurement
The clinical, anthropometric and analytical data collected
are shown in Table 1. The measurement procedure has
been described previously [16]. Hs-CRP was determined
by the nephelometric method (Beckman Instrument APS;
Beckman Coulter Inc., Fullerton, CA, USA) [17].Blood pressure
Office or clinical blood pressure
Measurement was obtained by performing three measure-
ments of systolic (SBP) and diastolic blood pressure
(DBP), using the average of the last two, with a validated
OMRON model M10 sphygmomanometer (Omron
Health Care, Kyoto, Japan), and following the recommen-
dations of the European Society of Hypertension [18]. The
mean of the last two measurements obtained by the nurse
of the research unit from the arm with high blood pres-
sure was used for the study.Home blood pressure (HBP)
Three measurements were made in the morning (be-
tween 6:00 and 9:00 a.m.), and three in the afternoon/
evening (between 6:00 and 9:00 p.m.), over a period of
7 days, with a minimum interval of one minute between
measurements, and excluding the first measurement and
the values corresponding to the first day of measure-
ment [19]. The same sphygmomanometer model used to
measure blood pressure in the office was employed.Ambulatory blood pressure monitoring (ABPM)
ABPM was performed on a day of standard activity, with
an adequate cuff for the size of the patient’s arm. A con-
trol system (Spacelabs 90207, Healthcare, Issaquah,
Washington, USA), validated according to the protocol
of the British Hypertension Society, was used [20]. The
records of readings considered to be valid were ≥ 80% of
the total. The monitor was programmed for obtaining
blood pressure measurements every 20 min during the
waking period and every 30 min during the resting
period. Individual correction was made of the waking
and sleeping hours reported by the patient.
Table 1 Characteristics of study patients, overall and by sex
Variable Overall (n = 258) Males (n = 153) Females (n = 105) P value
Age (years) 53.27 ± 12.01 52.18 ± 12.20 54,85 ± 11.60 0.080
Serum glucose (mg/dl) 87.69 ± 10.80 88.16 ± 11.53 86.99 ± 9.61 0.398
Glycated hemoglobin (%) 5.05 ± 0.54 5.06 ± 0.58 5.02 ± 0.48 0.566
Office BP (mmHg)
SBP 139.93 ± 16.75 141.35 ± 15.90 137.84 ± 17.81 0.099
DBP 88.34 ± 10.69 88.33 ± 10.53 88.37 ± 10.98 0.975
Pulse pressure 52.23 ± 12.82 53.61 ± 12.70 50.20 ± 12.79 0.036
Heart rate 72.37 ± 12.89 70.09 ± 12.62 75.74 ± 12.60 0.001
ABPM 24 hours (mmHg)
SBP 126.71 ± 12.83 127.66 ± 12.20 125.31 ± 13.63 0.149
DBP 78.72 ± 9.86 80.13 ± 9.58 76.65 ± 9.93 0.005
Pulse pressure 47.99 ± 9.50 47.53 ± 8.53 48.66 ± 10.76 0.348
Heart rate 71.92 ± 10.62 71.03 ± 11.47 73.24 ± 9.11 0.103
Home BP (mmHg)
SBP 127.23 ± 14.49 128.69 ± 13.55 125.11 ± 15.58 0.051
DBP 81.62 ± 9.85 81.92 ± 9.45 81.19 ± 10.43 0.557
Pulse pressure 45.60 ± 10.07 46.77 ± 9.01 43.91 ± 11.26 0.026
Heart rate 68.62 ± 9.17 67.35 ± 8.98 70.45 ± 9.18 0.007
Current smokers (%) 64 (24,8) 46 (30.1) 18 (17.1) 0.018
Obesity (%) * 70 (27,1) 45 (29.4) 25 (23.8) 0.320
BMI (kg/m2) 27.92 ± 3.83 28.30 ± 3.20 27.37 ± 4.55 0.054
Waist circumference (cm) 95.60 ± 11.12 99.45 ± 9.14 90.03 ± 11.41 p < 0.001
Dyslipidemia (%) 206 (79,8) 121 (79.1) 85 (81.0) 0.633
Total cholesterol (mg/dL) 208.96 ± 36.94 205.37 ± 35.13 214.27 ± 39.02 0.059
Triglycerides (mg/dL) 126.34 ± 73.35 135.95 ± 85.98 112.17 ± 45.96 0.011
LDL-cholesterol (mg/dL) 130.64 ± 33.00 129.59 ± 30.35 132.17 ± 36.62 0.546
HDL-cholesterol
(mg/dL)
53.28 ± 13.01 48.90 ± 10.94 59.73 ± 13.16 p < 0.001
No HDL-cholesterol
(mg/dL)
155,75 ± 36.48 156.50 ± 35.41 154.64 ± 38.15 0.692
Atherogénic Index 4,12 ± 1.13 4.39 ± 1.19 3.73 ± 0.92 p < 0.001
Cardiovascular risk
DAgostino
15.29 ± 12.52 19.19 ± 14.15 9.55 ± 6.19 p < 0.001
hs-CRP (mg/L) 2.73 ± 4.02 2.94 ± 4.81 2.41 ± 2.37 0.310
Fibrinogen, g/L 317.05 ± 61.39 314.57 ± 63.55 320.69 ± 58.21 0.441
Maximum IMT (mm) 0.88 ± 0.14 0.90 ± 0.15 0.86 ± 0.11 0.012
Mean IMT (mm) 0.71 ± 0.12 0.73 ± 0.13 0.69 ± 0.10 0.011
PWV (m/sec) 8.65 ± 2.06 8.66 ± 2.14 8.64 ± 1.96 0.952
CAIx 30.12 ± 11.66 26.59 ± 11.45 35.31 ± 9.95 p < 0.001
PAIx 92.52 ± 21.19 85.97 ± 19.13 102.06 ± 20.47 p < 0.001
AASI 0.37 ± 0.06 0.37 ± 0.06 0.38 ± 0.06 0.050
AASI-BPVR 0.16 ± 0.16 0.15 ± 0.17 0.18 ± 0.13 0.101
Awake-AASI 0.37 ± 0.06 0.37 ± 0.05 0.38 ± 0.06 0.061
Sleep-AASI 0.38 ± 0.15 0.38 ± 0.14 0.39 ± 0.16 0.534
HASI 0.59 ± 0.18 0.58 ± 0.20 0.61 ± 0.15 0.365
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Table 1 Characteristics of study patients, overall and by sex (Continued)
HASI-BPVR 0.29 ± 0.24 0.25 ± 0.26 0.35 ± 0.19 0.001
Antihypertensive Drugs (%) 101 (39.1) 61 (39.9) 40 (38.1) 0.774
Lipid-lowering Drugs (%) 48 (18.6) 31 (20.3) 17 (16.2) 0.409
Data for qualitative variables are expressed as n (%) and quantitative variables as mean ± standard deviation.
* Obesity: BMI ≥ 30 Kg/m²or Waist circumference≥ 88 cm in men and≥ 102 cm in women. SBP: Systolic blood pressure; DBP: Diastolic blood pressure; AMBP:
Ambulatory blood pressure monitoring; BMI, body mass index; hs-CRP: high-sensitive C-reactive protein; HDL, high density lipoprotein; LDL, lowdensity lipoprotein;
IMT: Intima Media Thickness; PWV: pulse wave velocity; CAIx: Central augmentation index; PAIx: Peripheral augmentation index, AASI: Ambulatory arterial stiffness
index, BPVR: Blood pressure variability ratio; HASI: Home arterial stiffness index.
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Assessment of carotid intima-media thickness (IMT)
Carotid ultrasound to assess IMT was performed by two
investigators trained for this purpose before starting the
study. The reliability of assessment was evaluated before
the study, using the intraclass correlation coefficient,
which showed values of 0.974 (95%CI: 0.935 to 0.990)
for intra-observer agreement on repeated measurements
in 20 subjects, and 0.897 (95%CI: 0.740 to 0.959) for
inter-observer agreement. According to the Bland-
Altman analysis, the limit of inter-observer agreement
was 0.022 (95%CI: -0.053 to 0.098), and the limit of
intra-observer agreement was 0.012 (95%CI: -0.034 to
0.059). A Sonosite Micromax ultrasound device paired
with a 5–10 MHz multifrequency high-resolution linear
transducer with Sonocal software was used for perform-
ing automatic measurements of CC-IMT, obtained auto-
matically 120 values, 10 measurements in each of the 12
projections, in order to optimize reproducibility. Mea-
surements were made of the common carotid artery
after the examination of a longitudinal section of 10 mm
at a distance of 1 cm from the bifurcation, performing
measurements in the near wall, and in the far wall in the
lateral, anterior and posterior projections, following an
axis perpendicular to the artery to discriminate two lines
- one for the intima-blood interface and the other for
the media-adventitia interface. Using mean average
values and maximum average values calculated automat-
ically by the software. The measurements were obtained
with the subject lying down, with the head extended and
slightly turned opposite to the exploratory side, follow-
ing the recommendations of the Manheim Carotid
Intima-Media Thickness Consensus [21].Pulse wave velocity (PWV) and peripheral (PAIx) and central
(CAIx) augmentation index
Were estimated through the SphymgoCor System (AtCor
Medical Pty Ltd Head Office, West Ryde, Australia). Using
the SphygmoCor System (Px Pulse Wave Analysis) by an
investigator, with the patient in the sitting position and
resting the arm on a rigid surface, pulse wave analysis was
made with a sensor in the radial artery, using mathemat-
ical transformation to estimate the aortic pulse wave. Thereliability of which was evaluated before the study began
using the CAIx intra-class correlation coefficient, which
showed values of 0.974 (95%CI: 0.936 to 0.989) for intra-
observer agreement on repeated measurements in 22 sub-
jects and according to the Bland-Altman analysis the lim-
its of intra-observer agreement was 0.454 (95%CI:−9.876
to 10.785). From the morphology of the aortic wave,
Central AIx was estimated using the following formula:
Increase in central pressure × 100/pulse pressure. Periph-
eral AIx was calculated as follows: (second peak systolic
blood pressure [SBP2]− diastolic blood pressure [DBP])/
(first peak SBP-DBP)× 100 (%). Using the SphygmoCor
System (Vx pulse wave velocity), and with the patient in
the supine position, the pulse wave of the carotid and fem-
oral arteries was analyzed, estimating the delay with re-
spect to the ECG wave and calculating the PWV. Distance
measurements were taken with a measuring tape from the
sternal notch to the carotid and femoral arteries at the
sensor location.
Ambulatory arterial stiffness index (AASI) and home
arterial stiffness index (HASI)
For AASI and HASI estimation, the regression slope of
diastolic on systolic blood pressure was computed for each
individual on the basis of 24-hour ABPM (AASI) and also
HBP readings (HASI) over 6 days. AASI as well as HASI
were defined as one minus the respective regression slope
of DBP on SBP. AASI was also computed from waking or
sleeping blood pressure. Blood pressure variability ratio
(BPVR) was defined as SD (SBP)/SD(DBP), AASI (BPVR)
as 1-[1/SD (SBP)/SD (DBP)] in 24-hour blood pressure
[22-24], and HASI (BPVR) as 1-[1/SD (SBP)/SD (DBP)]
over 7 days of HBP recording.
The individuals performing the different tests were
blinded to the clinical data of the patient. All organ
damage assessment measures were made within a period
of 10 days.
Statistical analysis
Continuous variables were expressed as the mean ±
standard deviation (SD), while frequency distributions
were used for qualitative variables. The difference in
means between two-category quantitative variables has
been analyzed using the Student t-test for independent
Table 2 Correlation of arterial stiffness measurement and high-sensitive C-reactive protein
Variable Overall (n = 258) Males (n = 153) Females (n = 105)
Office BP (mmHg)
SBP 0.048 0.038 0.054
DBP 0.040 0.045 0.031
Pulse pressure 0.026 −0.004 0.060
Heart rate 0.186** 0.206* 0.189
ABPM 24 hours (mmHg)
SBP 0.126* 0.196* 0.023
DBP 0.055 0.161* −0.125
Pulse pressure 0.115 0.100 0.145
Heart rate 0.246** 0.306** 0.144
Home BP (mmHg)
SBP 0.185** 0.212** 0.138
DBP 0.137* 0.188* 0.047
PP 0.134* 0.123 0.142
Heart rate 0.189** 0.200* 0.196
Total cholesterol (mg/dL) −0.004 0.044 −0.060
LDL-cholesterol (mg/dL) 0.063 0.094 0.031
HDL-cholesterol (mg/dL) −0.198** −0.138 −0.282**
No HDL-cholesterol (mg/dL) 0.063 0.083 0.034
Atherogenic Index 0.171** 0.141 0.211*
Ln Cardiovascular risk DAgostino 0.188** 0.238** 0.086
Waist circumference (cm) 0.235** 0.215** 0.275**
Maximum IMT (mm) 0.194** 0.290** 0.011
Mean IMT (mm) 0.174** 0.261** 0.010
PWV (m/sec) 0.280** 0.250** 0.319**
CAIx −0.048 0.067 −0.222*
PAIx 0.068 0.166* −0.058
AASI 0.067 −0.027 0.215*
AASI-BPVR −0.012 0.012 −0.049
Awake-AASI 0.057 −0.034 0.198
Sleep-AASI 0.093 0.005 0.240*
HASI −0.013 −0.044 0.057
HASI-BPVR −0.049 −0.059 0.004
BP: blood pressure; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; AMBP: Ambulatory blood pressure monitoring; HDL, high density lipoprotein; LDL,
low density lipoprotein; IMT: Intima Media Thickness; PWV: pulse wave velocity; CAIx: Central augmentation index; PAIx: Peripheral augmentation index, AASI:
Ambulatory arterial stiffness index, BPVR: Blood pressure variability ratio; HASI: Home arterial stiffness index.
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correlation coefficient was used to estimate the relation-
ship between quantitative variables. We performed linear
regression analysis using high-sensitive C-reactive pro-
tein as independent variables and using IMT, PWV and
CAIx as dependent variables. We have performed mul-
tiple linear regression analysis with interaction effects
(between gender and hs-CRP) using IMT, PWV and
CAIx as dependent variables and high-sensitiveC-reactive protein as independent variables, establishing
7 models: model 1, without adjusted; model 2, adjusting
for gender and interaction gender x hs-CRP, model 3,
adding age; model 4, adding the waist circumference;
model 5, adding 24 hours SBP and 24 hours heart
rate; model 6, adding Atherogenic Index (Atherogenic
Index =Total cholesterol/HDL-cholesterol); model 7,
adding Antihypertensive and Lipid-lowering Drugs. We
performed multiple linear regression analysis using IMT,
Figure 1 Simple linear regression lines, regression equations and r and P values showing the correlations between high-sensitive
C-reactive protein and pulse wave velocity, intima media thickness and central augmentation index.
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sensitive C-reactive protein as independent variables,
establishing 6 models: model 1, without adjusted; model
2, adjusting for age; model 3, adding the waist circumfer-
ence; model 4, adding SBP, ABPM 24 hours and heart
rate 24 hours; model 5, adding Atherogenic Index;
model 6, adding Antihypertensive and Lipid-lowering
Drugs. All analyzes were performed by gender and vari-
ables not normally distributed we used the neperian
logarithm (LN). The data were analyzed using the SPSS
version 18.0 statistical package (SPSS Inc., Chicago,
Illinois, USA).
Results
The clinical characteristics, cardiovascular risk factors,
blood pressure values, IMT, PWV, CAIx, PAIx, AASI,
HASI and antihypertensive and lipid-lowering drugs
considered globally and by sexes are reported in Table 1.
Women showed higher central and peripheral AIx
values and home arterial stiffness index-blood pressurevariability ratio (HASI-BPVR) values, while men showed
greater cardiovascular risk and common carotid IMT
values, without differences in hs-CRP.
Table 2 reflects the correlation among hs-CRP, risk
factors and IMT, PWV, CAIx, PAIx, AASI, HASI consid-
ered globally and according to sexes. Ambulatory
systolic (SBP) and diastolic blood pressure (DBP), car-
diovascular risk estimated from the Framingham equa-
tion, mean and minimum IMT, and peripheral AIx
(PAIx) were positively correlated to hs-CRP in men. In
women, HDL-cholesterol and central AIx (CAIx) were
negatively correlated, while the atherogenic index and
ambulatory arterial stiffness index (AASI) (24 hours and
resting) were positively correlated to hs-CRP. Waist cir-
cumference and PWV showed positive correlations in
both sexes.
Figure 1 shows the simple linear regression straight
lines of hs-CRP as independent variable and IMT max-
imum, PWV and AIx as dependent variables. For each
unit increase in hs-CRP, carotid IMT would increase
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(β 0.002, p = 0.918), while PWV would increase 0.07 m/
sec in men and 0.08 m/sec in women. Lastly, for each
unit increase in hs-CRP, the CAIx would decrease 2.5
units in women.
The interaction analysis, showed that the effect of hs-
CRP toward IMT maximum and CAIx depends of the
gender (P < 0.05) (Table 3).Table 3 Regression models with the high-sensitive C-reactive
with interaction effect
Over
Variable β P Value
Dependent variable:
IMT maximun
Model 1 0.031 0.002
Model 2 0.002 0.923
Model 3 −0.009 0.432
Model 4 −0.011 0.368
Model 5 −0.007 0.549
Model 6 −0.010 0.413
Model 7 −0.008 0.502
Dependent variable:
PWV
Model 1 0.070 0.000
Model 2 0.070 0.000
Model 3 0.050 0.000
Model 4 0.043 0.001
Model 5 0.028 0.035
Model 6 0.027 0.043
Model 7 0.027 0.046
Dependent variable:
CAIx
Model 1 −0.617 0.455
Model 2 −2.511 0.044
Model 3 −2.983 0.010
Model 4 −2.587 0.025
Model 5 −2.420 0.032
Model 6 −2.453 0.031
Model 7 −2.711 0.017
Model 1: C-reactive protein.
Model 2: Adjusted by Gender and interaction gender x hs-CRP. Gender (coded 1 for
Model 3: Adjusted bay Model 2 and age.
Model 4: Adjusted by Model 3 and waist circumference.
Model 5: Adjusted by Model 4 and 24 hours systolic blood pressure (SBP) and 24 ho
Model 6: Adjusted by Model 5 and atherogenic Index.
Model 7: Adjusted by Model 6 and Antihypertensive and Lipid-lowering Drugs.
Interaction gender x hs-CRP IMT maximum: Model 2 (p = 0.023); Model 3 (p = 0.011)
(p = 0.013).
Interaction gender x hs-CRP CAIx: Model 2 (p = 0.035); Model 3 (p = 0.042); Model 4
In the PWV, the interactions gender x hs-CRP, were not statistically significant.The multiple linear regression models showed that in
males, 8.4% (β= 0.049) of the variability of IMT could be
explained by hs-CRP – statistical significance being
maintained after the adjustments made in the different
models (R2 = 0.545, beta 0.026 and p = 0.016). In men,
6.7% of the variability of PWV could be explained by hs-
CRP (beta =0.066), versus 10.2% in women (beta =
0.078). Statistical significance was maintained afterprotein adjusted for each measure of arterial stiffness,
all (n = 258)
95%CI R2 Adjusted R2
0.011 to 0.052 0.037
−0.030 to 0.034 0.060
−0.033 to 0.014 0.491
−0.035 to 0.013 0.486
−0.031 to 0.016 0.516
−0.033 to 0.014 0.527
−0.032 to 0.016 0.525
0.040 to 0.100 0.078
0.040 to 0.101 0.071
0.025 to 0.075 0.371
0.018 to 0.069 0.377
0.002 to 0.054 0.432
0.001 to 0.053 0.442
0.000 to 0.053 0.440
−2.241 to 1.006 0.002
−4.956 to −0.066 0.131
−5.253 to −0.713 0.254
−4.845 to −0.329 0.247
−4.626 to −0.214 0.315
−4.675 to −0.231 0.311
−4.937 to −0.486 0.322
male and 0 for female).
urs Heart rate.
; Model 4 (p = 0.010) Model 5 (p = 0.012); Model 6 (p = 0.009); Model 7
(p = 0.050); Model 5 (p = 0.019); Model 6 (p = 0.020); Model 7 (p = 0.015).
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was lost in the next model with waist circumference. In
contrast, in women statistical significance was main-
tained to adjustment of the fourth model (age, waist cir-
cumference, 24-hour SBP and heart rate) (β= 0.043,
p = 0.030). In women, 4.9% of the variability of CAIx
could be explained by hs-CRP, statistical significance
being maintained after adjusting of the different models
(β=−3.134, p = 0.009). The association of hs-CRP to the
rest of the parameters used to assess arterial stiffness
disappeared after adjusting for age (Table 4).
Discussion
The present study shows that the correlation of hs-CRP
to the IMT, PWV, CAIx, PAIx, AASI, HASI in hyperten-
sive patients behaves differently in men and women. In
men, a positive correlation to IMT is observed, while in
women a negative correlation to CAIx and a positive
correlation to AASI is noted. PWV shows a positive cor-
relation in both sexes. After adjusting for age, waist cir-
cumference, 24-hour heart rate and SBP, atherogenicTable 4 Regression models with the high-sensitive C-reactive
Males (n = 153)
Variable β Sig. 95%CI
Dependent variable: IMT maximun
Model 1 0.049 0.000 0.022 to 0.075
Model 2 0.029 0.004 0.009 to 0.048
Model 3 0.025 0.013 0.005 to 0.045
Model 4 0.027 0.011 0.006 to 0.048
Model 5 0.026 0.013 0.006 to 0.047
Model 6 0.026 0.016 0.005 to 0.046
Dependent variable: PWV
Model 1 0.066 0.001 0.026 to 0.106
Model 2 0.040 0.019 0.007 to 0.074
Model 3 0.032 0.064 −0.002 to 0.066
Model 4 0.020 0.254 −0.015 to 0.056
Model 5 0.021 0.233 −0.014 to 0.056
Model 6 0.018 0.308 −0.017 to 0.053
Dependent variable: CAIx
Model 1 0.839 0.420 −1.211 to 2.889
Model 2 −0.182 0.847 −2.047 to 1.682
Model 3 0.020 0.983 −1.837 to 1.877
Model 4 1.160 0.218 −0.692 to 3.011
Model 5 1.135 0.233 −0.737 to 3.008
Model 6 1.130 0.238 −0.757 to 3.017
Model 1: C-reactive protein.
Model 2: Adjusted for Age.
Model 3: Adjusted for model 2 and Waist circumference.
Model 4: Adjusted for model 3 and 24 hours Systolic blood pressure and 24 hours H
Model 5: Adjusted for model 4 and atherogenic Index.
Model 6: Adjusted for model 5 and Antihypertensive and Lipid-lowering Drugs.index and the use of antihypertensive and lipid-lowering
drugs, the correlation of hs-CRP to carotid IMT in men
and to CAIx in women was seen to be maintained. The
association to PWV was maintained in men only on
adjusting for age, while in women the correlation was
maintained with waist circumference, SBP and 24-hour
heart rate, after adjusting for age.
In coincidence with the data published by Kaptoge [5],
the hs-CRP concentration was higher in males, though
CAIx was found to be higher in women than in men, in
agreement with other authors [11,25]. The global ana-
lysis of the sample revealed correlations between hs-CRP
and the different risk factors similar to those published
by other investigators [5].
In coincidence with the findings of other studies, mean
IMT was greater in men than in women [26]. The asso-
ciation between IMT and hs-CRP only proved significant
in men – and this association was maintained after
adjusting for the different models used. The studies that
have examined the relationship between hs-CRP and
carotid IMT in the general population have yieldedprotein adjusted for each measure of arterial stiffness
Females (n = 105)
AdjustedR2 β Sig. 95%CI AdjustedR2
0.084 0.002 0.918 −0.028 to 0.032 0.000
0.511 −0.009 0.452 −0.031 to 0.014 0.430
0.508 −0.007 0.546 −0.031 to 0.016 0.425
0.537 −0.003 0.827 −0.026 to 0.021 0.456
0.549 −0.006 0.647 −0.030 to 0.018 0.459
0.545 −0.003 0.782 −0.028 to 0.021 0.454
0.067 0.078 0.001 0.031 to 0.124 0.102
0.370 0.064 0.001 0.025 to 0.103 0.372
0.381 0.060 0.004 0.019 to 0.100 0.371
0.412 0.043 0.030 0.004 to 0.081 0.482
0.420 0.034 0.086 −0.005 to 0.072 0.504
0.427 0.029 0.151 −0.011 to 0.070 0.497
0.004 −2.511 0.027 −4.729 to −0.293 0.049
0.197 −2.799 0.012 −4.967 to −0.630 0.092
0.172 −2.476 0.031 −4.718 to −0.235 0.094
0.279 −2.689 0.019 −4.929 to −0.449 0.174
0.273 −2.745 0.019 −5.026 to −0.464 0.172
0.270 −3.134 0.009 −5.456 to −0.812 0.204
eart rate.
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confirmed that an increase in hs-CRP implies an in-
crease in IMT [27-30]. In this same line, in hypertensive
patients some authors have reported a positive associ-
ation to the development and progression of carotid ath-
erosclerosis [8,31,32], even in cases of recently
diagnosed hypertension [33]. However, Choi et al. [34]
observed no association between hs-CRP and carotid
atherosclerosis in either hypertensive patients or in
normotensive individuals. Likewise, the behavior accord-
ing to patient sex is not clear. In effect, while Makita
et al. [27] concluded that in the general population hs-
CRP may serve as a surrogate marker for atheroma
plaque formation in men but not in women, Sanders
et al. [26] found IMT to be significantly associated to
hs-CRP in women but not in men, after adjusting for
risk factors – the conclusion being that the relationship
between hs-CRP and the progression of early carotid
atherosclerosis shows gender differences.
Carmel et al. [12], in a prospective study of the associ-
ation between PWV and hs-CRP, recorded a positive as-
sociation similar to that seen in the present study,
though in this case the behavior between sexes was
found to be different after adjustment in the multiple re-
gression analysis. This suggests that inflammation plays
a role in aortic stiffness as assessed with PWV, but that
patient sex could exert an influence.
In our study, hs-CRP was correlated negative with
CAIx in Woman (r =−0.222), though Janner et al., in the
general population, only observed a relationship in
young males [11]. These data coincide with the findings
of Carmel et al. [12] in men, where after adjusting in
multivariate models only fibrinogen remained as a weak
predictor between CAIx and hs-CRP. This relationship,
could be explained, by CAIx values are higher in women
and decrease with increasing BMI. The BMI may be a
confounding factor in this negative correlation of hs-
CRP with CAIx.
On the other hand, the disparity of results relating hs-
CRP to PWV and CAIx in males reinforces the idea that
the findings are not inter-exchangeable and differ
according to patient sex [35].
The present study has some limitations, including its
cross-sectional design, which does not allow us to estab-
lish cause-effect relationships between hs-CRP and the
arterial stiffness parameters. In turn, the study popula-
tion was recruited through consecutive sampling, which
precludes generalization of the results. Nevertheless, the
distribution of the population analyzed is similar to that
of the real-life population of hypertensive subjects with
cardiovascular risk factors and no previous cardiovascu-
lar disease. Lastly, estimation of the central PWV based
on the radial PWV, using the transference function, has
been questioned [36-38].Conclusions
In conclusion, this study shows that after adjusting for
age, cardiovascular risk factors and the use of antihyper-
tensive and lipid-lowering drugs, hs-CRP exhibits a posi-
tive correlation to IMT in men, a negative correlation to
CAIx in women, and a positive correlation to PWV in
both sexes. Therefore, in order to clarify the role of hs-
CRP in relation to the parameters commonly used to as-
sess arterials stiffness in both males and females, pro-
spective studies must be carried out to clarify this
association and to define the differences between sexes.
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